SynthesisAdvances in therapy2017
Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
Synthesis in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Tolerability and efficacy of chemosaturation in combination with systemic therapy for metastatic uveal melanoma.International journal of cancer · 2026Article
- Observational
- Intrahepatic cholangiocarcinoma as a unique subtype: key updates from current guidelines.Journal of cancer research and clinical oncology · 2025Article
- Advanced targeted microsphere embolization for arteriovenous malformations: state-of-the-art and future directions.Neuroradiology · 2025Review
- Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer.Cancers · 2024Article
- Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation.ESMO gastrointestinal oncology · 2024Article
- Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 and 2021.Therapeutic advances in medical oncology · 2024Article
- Heparin reversal with protamine sulfate after Percutaneous Hepatic Perfusion (PHP): is less more?Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- [Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)].Die Anaesthesiologie · 2023Review
- [Thrombotic occlusion of the extracorporeal circulation during hepatic chemosaturation despite targeted anticoagulation : A case report].Die Anaesthesiologie · 2022Article
- Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience.BMC medical imaging · 2022Review
- Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.Cancers · 2021Article
- Radial Artery Access for Hepatic Chemosaturation: The First Description of Technical Feasibility.Cureus · 2021Article
- Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.Clinical & experimental metastasis · 2020Article
- The evolution of interventional oncology in the 21st century.The British journal of radiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Hepatic CHEMOSAT
fundingDelcath Systems Inc., New York, NY, USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.